Want to see HYPR full AI Analyst Report?
HYPR Stock Chart & Stats
$0.87
$0.05(4.83%)
At close: 4:00 PM EDT
$0.87
$0.05(4.83%)
Day’s Range― - ―
52-Week Range$0.74 - $1.94
Previous CloseN/A
Volume31.66K
Average Volume (3M)953.06K
Market Cap
$82.42M
Enterprise Value$103.38M
Total Cash (Recent Filing)$43.46M
Total Debt (Recent Filing)$13.41M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Nov 09, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding90,993,380
10 Day Avg. Volume1,912,247
30 Day Avg. Volume953,059
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)2.25
Price to Sales (P/S)6.80
P/FCF Ratio-3.17
Enterprise Value/Market Cap1.25
Enterprise Value/Revenue6.25
Enterprise Value/Gross Profit12.16
Enterprise Value/Ebitda-3.12
Forecast
1Y Price Target
$2.03Price Target Upside133.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.34
Revenue Forecast (FY)$20.17M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthAccelerating revenue and broader deployments across health systems, offices, mobile settings, and international markets indicate that Hyperfine is expanding beyond early pilots. Continued growth across several commercial verticals could improve operating leverage and support a more durable commercialization trajectory.
Gross Margin ExpansionSustained gross margins above 50% show materially improved unit economics compared with earlier periods, when margins were much lower. Maintaining this level while placements increase would give Hyperfine more contribution toward operating expenses and strengthen the foundation for eventual profitability.
Product And Clinical DifferentiationClinical evidence supports the value of portable MRI in faster bedside access and demonstrates meaningful agreement with conventional imaging. These results can strengthen hospital adoption, expand use beyond traditional radiology suites, and reinforce differentiation for Hyperfine’s hardware and software platform.
Bears Say
Persistent Losses And Cash BurnThe company continues to consume substantial cash while revenue remains modest, showing that commercial growth has not yet covered its operating and investment base. Even with improving burn, ongoing losses may require sustained cost discipline or future financing before the business becomes self-funding.
Early-Stage Commercial ScaleStrong percentage growth is being generated from a small revenue and placement base, so individual customer decisions can materially affect reported results. Limited absolute scale also means Hyperfine has not yet demonstrated that its commercial model can consistently absorb costs and produce durable operating leverage.
Nasdaq Listing RiskThe bid-price deficiency creates an ongoing corporate risk even though the shares remain listed today. Hyperfine must regain compliance by March 16, 2027, or pursue an extension and other actions, adding execution pressure and potentially complicating capital-market flexibility during its scaling phase.
Hyperfine News
HYPR FAQ
What was Hyperfine’s price range in the past 12 months?
Hyperfine lowest stock price was $0.74 and its highest was $1.94 in the past 12 months.
What is Hyperfine’s market cap?
Hyperfine’s market cap is $82.42M.
When is Hyperfine’s upcoming earnings report date?
Hyperfine’s upcoming earnings report date is Nov 09, 2026 which is in 19 days.
How were Hyperfine’s earnings last quarter?
Hyperfine released its earnings results on Aug 06, 2026. The company reported -$0.09 earnings per share for the quarter.
Is Hyperfine overvalued?
According to Wall Street analysts Hyperfine’s price is currently Undervalued.
Does Hyperfine pay dividends?
Hyperfine does not currently pay dividends.
What is Hyperfine’s EPS estimate?
Hyperfine’s EPS estimate is -0.08.
How many shares outstanding does Hyperfine have?
Hyperfine has 90,993,380 shares outstanding.
What happened to Hyperfine’s price movement after its last earnings report?
Hyperfine reported an EPS of -$0.09 in its last earnings report. Following the earnings report the stock price went down -2.749%.
Which hedge fund is a major shareholder of Hyperfine?
Currently, no hedge funds are holding shares in HYPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hyperfine Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.03 (133.72% Upside)
$2.03 (133.72% Upside)
Blogger Sentiment
Neutral
HYPR Sentiment 50%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 100.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $12.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.23%
12-Months-Change
Fundamentals
Return on Equity
-100.30%
Trailing 12-Months
Asset Growth
39.27%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Hyperfine
Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners. The company also offers support and technical assistance services, as well as Hyperfine Image Viewer, a cloud picture archiving and communication system. It serves intensive care units, neurology offices, emergency departments, and comprehensive and primary stroke accredited facilities through direct sales and distributors in the United States, Canada, the United Kingdom, other European and Middle Eastern markets, Australia, and New Zealand. The company was founded in 2014 and is based in Guilford, Connecticut.
HYPR Company Deck
HYPR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and commercial progress: double-digit revenue and unit growth, sustained gross margins above 50%, improved cash burn, strengthened balance sheet via ATM proceeds, meaningful clinical evidence (PRIME, NEURO PMR), regulatory approvals (CE/UKCA) and clear product roadmaps (contrast labeling, AI-enabled software). Notable challenges remain, including a sizable ongoing net loss, persistent (though improving) cash burn, modest absolute revenue and unit volume, timing sensitivity to IDN budget cycles, and pending regulatory label expansion for contrast. Management reiterated full-year guidance and emphasized identifiable growth drivers, suggesting confidence in conversion of recent momentum into scale.View all HYPR earnings summariesHYPR Stock 12 Month Forecast
Average Price Target
$2.03
▲(133.72% Upside)
Technical Analysis
Ownership Overview
21.06% Insiders
4.68% Mutual Funds
0.40% Other Institutional Investors
66.46% Public Companies and
Individual Investors